Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% Zacks Investment Research - Wed Nov 20, 9:38AM CST

Shares of Grifols GRFS lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for €6.45 billion...

CTMX : 0.8740 (+0.45%)
CSTL : 28.45 (-1.45%)
GRFS : 8.36 (-2.79%)
SPRO : 1.1989 (-0.09%)
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
FATE Presents Encourgaing Data From Lupus Study, Stock Gains Zacks Investment Research - Tue Nov 19, 2:10PM CST

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.Data showed...

IMCR : 32.42 (-0.43%)
CSTL : 28.45 (-1.45%)
FATE : 2.23 (+0.45%)
SPRO : 1.1989 (-0.09%)
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus Zacks Investment Research - Wed Nov 13, 11:26AM CST

Fate Therapeutics FATE reported a loss of 40 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 42 cents. The company reported a loss of 46 cents per...

IMCR : 32.42 (-0.43%)
CSTL : 28.45 (-1.45%)
ANIP : 54.30 (-1.45%)
FATE : 2.23 (+0.45%)
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up Zacks Investment Research - Wed Nov 13, 11:10AM CST

Axsome Therapeutics, Inc. AXSM incurred an adjusted loss of $1.34 per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $1.38. The company had incurred a loss...

JAZZ : 122.00 (+2.31%)
CSTL : 28.45 (-1.45%)
ANIP : 54.30 (-1.45%)
AXSM : 92.30 (-2.43%)
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark Zacks Investment Research - Wed Nov 13, 10:54AM CST

SpringWorks Therapeutics, Inc. SWTX incurred a loss of 72 cents per share in the third quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had reported...

IMCR : 32.42 (-0.43%)
CSTL : 28.45 (-1.45%)
ANIP : 54.30 (-1.45%)
SWTX : 37.44 (-1.29%)
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised Zacks Investment Research - Tue Nov 12, 11:54AM CST

Mirum Pharmaceuticals, Inc. MIRM incurred a loss of 30 cents per share in third-quarter 2024, much narrower than the Zacks Consensus Estimate of a loss of 45 cents. The company had reported a loss of 57...

IMCR : 32.42 (-0.43%)
MIRM : 43.69 (+3.80%)
CSTL : 28.45 (-1.45%)
ANIP : 54.30 (-1.45%)
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus Zacks Investment Research - Mon Nov 11, 10:16AM CST

Rocket Pharmaceuticals, Inc. RCKT incurred a loss of 71 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 78 cents. In the year-ago quarter, the company...

FOLD : 9.59 (+0.74%)
IMCR : 32.42 (-0.43%)
CSTL : 28.45 (-1.45%)
RCKT : 13.04 (-0.91%)
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up Zacks Investment Research - Fri Nov 8, 10:44AM CST

Puma Biotechnology, Inc. PBYI reported third-quarter 2024 adjusted earnings of 45 cents per share, which beat the Zacks Consensus Estimate of 35 cents. In the year-ago quarter, the company had reported...

FOLD : 9.59 (+0.74%)
IMCR : 32.42 (-0.43%)
PBYI : 2.84 (+3.65%)
CSTL : 28.45 (-1.45%)
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down Zacks Investment Research - Fri Oct 25, 10:18AM CDT

Alkermes plc ALKS reported adjusted earnings from continuing operations of 73 cents per share for third-quarter 2024, which missed the Zacks Consensus Estimate of 78 cents. The company had reported adjusted...

CSTL : 28.45 (-1.45%)
ELEV : 0.6102 (+5.01%)
FATE : 2.23 (+0.45%)
ALKS : 27.91 (+1.56%)
VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements
VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements Zacks Investment Research - Thu Oct 24, 9:28AM CDT

Viking Therapeutics VKTX reported third-quarter 2024 loss per share of 22 cents, narrower than the Zacks Consensus Estimate of a loss of 24 cents. The company had incurred a loss of 23 cents per share...

FOLD : 9.59 (+0.74%)
VKTX : 52.00 (+0.91%)
CSTL : 28.45 (-1.45%)
FATE : 2.23 (+0.45%)

Barchart Exclusives

Is Snowflake Stock a Buy, Sell, or Hold After Q3 Earnings? Barchart - 4 minutes ago
Snowflake delivered better-than-expected Q3 results and provided upbeat guidance, lifting investor sentiment. Its stock jumped about 20% in after-hours trading. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot